AFFY Key Stats
|Revenue (Quarterly YoY Growth)||-80.94%|
|EPS Diluted (TTM)||-2.817|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-104.21M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- AFFYMAX INC Files SEC form 10-Q, Quarterly Report Nov 5
- New Data Show Omontys At Least 4x Worse Than Reported: Now 22 Suspected Deaths Seeking Alpha Oct 14
- IART Accomplishes Shoulder Implant - Analyst Blog Zacks Sep 24
- Affymax downgraded by WBB Securities Sep 18
- Just Like Omontys.com, Affymax Is Likely To Disappear Sep 10
- Don't Believe In Affymax - The Stock Is Probably Worthless Aug 29
- Affymax: Getting The Facts Straight Aug 29
- Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen Aug 28
- Affymax: Putting The Pieces Together Aug 24
- AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits Aug 20
AFFY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Affymax is down 96.51% over the last year vs S&P 500 Total Return up 30.05%, Amgen up 30.52%, and Cytokinetics up 61.89%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for AFFY
Pro Strategies Featuring AFFY
Did Affymax make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Affymax, Inc., is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions.